Puma Biotechnology Common Stock Total Equity Over Time

PBYI Stock  USD 3.00  0.10  3.45%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Puma Biotechnology Performance and Puma Biotechnology Correlation.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
  
The current Common Stock Total Equity is estimated to decrease to 4,275.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.417
Earnings Share
0.47
Revenue Per Share
5.045
Quarterly Revenue Growth
0.435
Return On Assets
0.0973
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Common Stock Total Equity Analysis

Compare Puma Biotechnology and related stocks such as Ultragenyx, Crinetics Pharmaceuticals, and Arvinas Common Stock Total Equity Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
RAREKKKK32 K39 K41 K44 K51 K58 K67 K69 K70 K80.5 K44.1 K
CRNX1000100010001000100010001000100024 K210.8 M336.5 M336.5 M336.5 M387 M406.3 M
ARVN947.5 K947.5 K947.5 K947.5 K947.5 K947.5 K947.5 K1.2 M31.2 K38.5 K48.5 K100 K100 K90 K85.5 K
RVMDKKKKKKKKKKKKK9.2 K6.6 K
KURA500500500500500KKKKKKKK8.1 K8.5 K
TSVTKKKKKKKKKKKKK4.6 K3.3 K
IOVA5.1 K3.2 K3.4 K3.4 K1.4 KKKKKKKKK6.9 K4.1 K
SRPT3.1 M13 KKKKKKKKKKKK8.1 K7.7 K
MDGL1000KKK11 K14 K1.2 K1000KKKKK2.3 K4.3 K
VKTX50.050.050.052.060.097.0208358100010001000100010001.1 K583
HEPA9009009001.8 K1.8 K2.2 K3.2 K7.6 K1.7 K3753.2 K7.6 K7.6 K8.8 K9.2 K
PTCT13313354524.3 K33 K34 K34 K42 K51 K62 K70 K71 K72 K82.8 K45.3 K
HRTX200 KMM237 K292 K361 K394 K646 K782 K903 K913 KMM1.2 M658 K
CHRS1000100010001000KKKKKKKKK9.2 K5.6 K
LRMR27 K27 K27 K27 K27 K27 K27 K27 K37 K37 K15 K43 K43 K49.5 K33.5 K
MGNX10.5 K10.5 K11 K251.8 K280 K343 K349 K369 K424 K490 K562 K613 K617 K709.5 K396 K

Puma Biotechnology and related stocks such as Ultragenyx, Crinetics Pharmaceuticals, and Arvinas Common Stock Total Equity description

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

My Equities

My Current Equities and Potential Positions

Puma Biotechnology
PBYI
ClassificationCancer Fighters
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 3.0
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
Check out Puma Biotechnology Performance and Puma Biotechnology Correlation.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Puma Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Puma Biotechnology technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Puma Biotechnology trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...